Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrasTUCAN: Trastuzumab + Tucatinib + Vinorelbine in HER2+ Advanced Breast Cancer
NCT05583110Phase 2Terminated
- Sponsor
- GEICAM
- Start
- Mar 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib in HER2-positive breast cancer, sponsored by GEICAM. Primary endpoint: Objective Response Rate at 26 months. Started Mar 2023; status: terminated.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05583110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583110.